Videos

Treatment Options for a Young, Fit Patient Newly Diagnosed with AML

Eunice S. Wang, MD, shares first-line treatment approaches for patients with NPM1-mutant AML, discussing current clinical data.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

Implementing Real-world Evidence into Clinical Practice in NDMM

The panel discuss the need for personalized treatment approaches for young, fit patients with newly diagnosed acute myeloid leukemia, as well as when transplant should be considered.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

Assessing and Supporting Frail Patients with NDMM

Clinical pearls for community oncologists concerning the real-world application of existing treatments while considering feasibility, cost, and ease of care.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

Long-Term Followup With Talquetamab in Relapsed/Refractory MM: Infection Rates

Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.

Ajai Chari, MD;Carolina D. Schinke, MD

Practical Considerations for Talquetamab Use in Relapsed/Refractory Multiple Myeloma

Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD;Carolina D. Schinke, MD

Pembrolizumab Plus Axitinib Versus Sunitinib for First-Line Treatment of Advanced Clear Cell RCC

Following their review of data from MonumenTAL-1, Ajai Chari, MD, and Carolina Schinke, MD, share practical considerations for real-world use of talquetamab in relapsed/refractory multiple myeloma.

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

Lenvatinib Plus Pembrolizumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma (aRCC)

Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

Diagnosis, Biomarker Testing, and Optimizing Treatment Selection for Patients with AML

Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.

Innovations in MPN Therapy: Ongoing Trials and Latest Findings

Drs. Koprivnikar, McCloskey, and Cho delve into the diagnostic process in acute myeloid leukemia (AML), treatment approaches for AML, and factors influencing treatment selection.

Diagnosing Bladder Cancer: Best Practices in Workup and Staging

A closer look at the current unmet needs in MPN treatment, ongoing trials, and recent updates such as the MOMENTUM and FREEDOM trials.

Petros Grivas, MD, PhD;Emily S. Weg, MD;Lisa Adams, PA-C;Nerina T. McDonald, PA-C

Patient Case Review: What is a Typical Presentation of Bladder Cancer?

Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.

Petros Grivas, MD, PhD;Emily S. Weg, MD;Lisa Adams, PA-C;Nerina T. McDonald, PA-C

Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM

Expert panelists review a patient presentation of bladder cancer and consider the typical signs and symptoms that may lead to a diagnosis.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting

Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

The Future of Treatment for Patients with MDS

Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.

Targeting CD47 in MDS: Reviewing the CD47 Pathway and Key Trial Data

Dr. Daver anticipates how the MDS landscape will evolve over time, emphasizing the importance of adopting targeted therapies.

Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma

Subject-matter expert provides an overview of the CD47 pathway and shares how emergent trial data are impacting the MDS treatment landscape.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer

Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.

Joshua K. Sabari, MD;Misako Nagasaka, MD

Application of Bispecific Therapy in Clinical Practice

Shared insight on uncommon EGFR mutations in patients with non–small cell lung cancer and how they fit into the larger disease paradigm.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Paradigm of NGS Testing in Patients With Advanced NSCLC

Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.

Joshua K. Sabari, MD;Misako Nagasaka, MD

T-DXd May be ‘Practice Changing’ in HER2+ Gynecologic Cancers

Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.

Ritu Salani, MD

July 8th 2023

Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.

Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.

Relapsed/Refractory Multiple Myeloma: Factors in Selecting Later-Line Therapy

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

MAIA Trial: DRd vs Rd in Transplant-Ineligible Patients with MM

Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Patient Profile 2: A 79-Year-Old with Multiple Myeloma

Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Effect of MRD Positivity on Treatment Decisions in Colorectal Cancer

The expert panel presents the case of a patient with multiple myeloma and discusses evaluating transplant eligibility in patients with MM.

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Joleen M. Hubbard, MD;Aparna Raj Parikh, MD, MS

Patient Profile: A 55-Year-Old With Colon Cancer

The expert panel discusses how MRD positivity affects treatment decisions for patients with colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Joleen M. Hubbard, MD;Aparna Raj Parikh, MD, MS

Role of CAR T-cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Experts on colorectal cancer present a patient case, offer their initial impressions, and discuss disease staging.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Unmet Needs and Future Perspectives in Multiple Myeloma

Before closing out their module on relapsed/refractory multiple myeloma, key opinion leaders reflect on the role of CAR T-cell therapy and patient access to care.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Relapsed/Refractory Multiple Myeloma: Managing Patients on Bispecific Therapy

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma

Centering discussion on bispecific therapy, panelists consider dosing strategies and adverse event management in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN